MedPath

Evaluation of the effect of the antiepiletic levetiracetum on seizure control and expression of MGMT in patients with gliomas (Phase II clinical trial)

Not Applicable
Recruiting
Conditions
glioma
Registration Number
JPRN-UMIN000017531
Lead Sponsor
Department of Neurosurgery, Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1. History of allergy to the ingredients of levetiracetum or pyrrolidones 2. History of status epilepticus or intractable epilepsy 3. Serious psychotic disorder 4. Pregnant or breast feeding women 5. Severe heart disease, or liver dysfunction, or renal dysfunction

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath